BREAST CANCER PATIENTS' PREFERENCES FOR LOCAL AND SYSTEMIC THERAPY
Author(s)
Jesse Lee Cooke, BA, BS, PhD, Assistant Professor1, C. Daniel Mullins, PhD, Professor and Chair2, Katherine Tkaczuk, MD, Associate Professor of Medicine and Oncology and Director, Breast Evaluation Program3, Claudia R Baquet, MD, MPH, Professor of Medicine; Director UM NIH Comprehensive Center for Health Disparities Research Outreach and Training41Xavier University - Louisiana College of Pharmacy, New Orleans, LA, USA; 2 University of Maryland School of Pharmacy, Baltimore, MD, USA; 3 University of Maryland Greenebaum Cancer Center, Baltimore, MD, USA; 4 University of Maryland School of Medicine, Baltimore, MD, USA
OBJECTIVES: To determine the predictors of breast cancer patients' (BCPs) willingness to accept local and systemic therapy. METHODS: Cross-sectional survey of BCPs ages 36-80 at the University of Maryland Greenebaum Cancer Center, Baltimore, MD. Since “treatment” is considered a “short-term” health state, the chained procedure for the time trade-off (TTO) was used to assess TTO. Willingness to accept therapy was determined using “minimum cancer-free years to accept therapy” (CFYs) as the dependent variable. The number of CFYs was calculated based upon BCPs TTO responses for mastectomy (MRM), breast-conserving therapy (BCT), chemotherapy (CTX) and tamoxifen (TAM). Demographic and clinical data were abstracted from medical records. Tobit regression models were used for multivariate analyses. RESULTS: Mean age=56.0 years (SD±9.43, n=77); 58.2% were white; 75.6% had early stage cancer. BCPs required more CFYs (median=4) to accept MRM than to accept BCT, CTX, or TAM (median 1 year for each). For all forms of therapy, the mode=0, suggesting that BCPs were willing to accept therapy even if it provided no additional CFYs. Late stage patients required more CFYs to accept TAM (ß=6.61, p=0.0489); similarly late stage patients in good physical health required more CFYs to have MRM (ß=0.50, p=0.0322). Treatment-experienced BCPs were more willing to accept that type of therapy than those who were treatment-naïve. Younger patients (<65) required fewer CFYs to accept chemotherapy (age group 50-54, ß=-4.77, p=0.0403; 55-59, ß=-7.25, p=0.0019). Being non-white and having less education were associated with requiring fewer CFYs to accept to accept CTX (ß=-3.86, p=0.0087; ß=-5.10, p=0.0193, respectively). CONCLUSION: BCPs required relatively few CFYs to accept treatment. Willingness-to-accept fewer CFYs for CTX among those with less education and of younger age is consistent with treatment patterns previously-published. The fact that non-whites (primarily African Americans) required fewer CFYs to accept CTX appears in contrast to observed underutilization of CTX among African American BCPs.
Conference/Value in Health Info
2007-05, ISPOR 2007, Arlington, VA, USA
Value in Health, Vol. 10, No.3 (May/June 2007)
Code
WH1
Topic
Methodological & Statistical Research, Patient-Centered Research
Topic Subcategory
Modeling and simulation, Patient-reported Outcomes & Quality of Life Outcomes
Disease
Oncology, Reproductive and Sexual Health
Explore Related HEOR by Topic